Moteur de recherche d’entreprises européennes
Financement de l’UE (6 000 000 €) : Mécanismes moléculaires associant la douleur chronique à la fatigue, aux troubles affectifs, aux maladies cardiovasculaires et à la comorbidité totale Hor27/11/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Mécanismes moléculaires associant la douleur chronique à la fatigue, aux troubles affectifs, aux maladies cardiovasculaires et à la comorbidité totale
Chronic pain (CP) is the leading cause of disability, and is strongly associated with fatigue, anxiety and depression ─ also major contributors to disability, and with cardiovascular disease (CVD) and mortality. Twin studies indicate that these associations are a consequence of common causal mechanisms. The main objective of PainFACT is to identify these mechanisms. Using hypothesis-free genomic, proteomic, transcriptomic and brain-imaging discovery in available human studies and in a large cohort of outbred mice with multiple comorbidities, we aim to identify biomarkers that are associated across conditions. Predictive algorithms will be developed through machine learning techniques and tested in prospective analysis. Mendelian randomization approaches will be applied to test for causality. Mechanistic studies will be carried out in validated behavioral and atherosclerotic mouse models. Predictive markers will be tested as possible mediators of effects of lifestyle and obesity. Unique features of this program of research is the strong emphasis on experimental pain models and brain imaging techniques, facilitating translation of findings between mice and humans, and exploitation of the largest study of experimental pain worldwide and of multiple clinical datasets ranging in size from tens of thousands to 1.1 million. A custom protein panel will be developed together with sex and age stratified algorithms, with expected impact for the prediction and monitoring of disease and comorbidity, and for tracking effects of life-style changes. It is also expected that PainFACT results will have major impact on the diagnostic criteria and classification of affective disorders and CP. The identification of novel causal biomarkers will provide new targets for development of medicines and yield new insight into the causes of comorbidity.
| ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 250 000 € |
| Folkehelseinstituttet | 1 092 876 € |
| Institut National de la Sante et de la Recherche Medicale | 0,00 € |
| Islensk Erfdagreining EHF | 810 000 € |
| Oslo Universitetssykehus HF | 807 750 € |
| Quibim SL | 250 393 € |
| Tataa Biocenter AB | 1 092 454 € |
| Thjonustumidstod Rannsoknaverkefnases | 0,00 € |
| Universidad Pompeu Fabra | 800 528 € |
| Universite de Strasbourg | 896 000 € |
https://cordis.europa.eu/project/id/848099
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.